Results 181 to 190 of about 13,150,510 (391)

Inhibitor of DNA binding‐1 is a key regulator of cancer cell vasculogenic mimicry

Molecular Oncology, EarlyView.
Elevated expression of transcriptional regulator inhibitor of DNA binding 1 (ID1) promoted cancer cell‐mediated vasculogenic mimicry (VM) through regulation of pro‐angiogenic and pro‐cancerous genes (e.g. VE‐cadherin (CDH5), TIE2, MMP9, DKK1). Higher ID1 expression also increased metastases to the lung and the liver.
Emma J. Thompson, Emma L. Dorward, Kristyn Jurrius, Nathalie Nataren, Markus Tondl, Kay K. Myo Min, Michaelia P. Cockshell, Anahita Fouladzadeh, John Toubia, Mark DeNichilo, Delphine Merino, Claudine S. Bonder   +11 more
wiley   +1 more source

NASA's Chemical Transfer Propulsion Program for Pathfinder [PDF]

Pathfinder is a research and technology project, with specific deliverables, initiated by the National Aeronautics and Space Administration (NASA) which will strengthen the technology base of the United States civil space program in preparation for ...
Berkopec, Frank D., Hannum, Ned P., Zurawski, Robert L.   +2 more
core   +1 more source

XII International scientific-technical conference «High chemical technologies-2008»

Тонкие химические технологии, 2008
XII International scientific-technical conference is devoted to problems of: chemistry and technology of organic and inorganic materials, chemistry and technology medical products and biologically active substances, ecological and economic problems of ...
V. D. Yulovskaya, V. S. Timofeev
doaj  

CHEMICAL TECHNOLOGY DIVISION, UNIT OPERATIONS SECTION MONTHLY PROGRESS REPORT FOR DECEMBER 1956

, 1957
J.C. Bresee, J.T. Long, E.O. Nurmi, C.D. Watson   +3 more
openalex   +2 more sources

MET and NF2 alterations confer primary and early resistance to first‐line alectinib treatment in ALK‐positive non‐small‐cell lung cancer

Molecular Oncology, EarlyView.
Alectinib resistance in ALK+ NSCLC depends on treatment sequence and EML4‐ALK variants. Variant 1 exhibited off‐target resistance after first‐line treatment, while variant 3 and later lines favored on‐target mutations. Early resistance involved off‐target alterations, like MET and NF2, while on‐target mutations emerged with prolonged therapy.
Jie Hu, Ning Ding, Xiaobo Xu, Yedan Chen, Yong Zhang, Jingwen Liu, Jiebai Zhou, Hairong Bao, Donghui Zhang, Yijun Song, Yang Shao, Yuanlin Song   +11 more
wiley   +1 more source

CHEMICAL TECHNOLOGY DIVISION UNIT OPERATIONS SECTION MONTHLY PROGRESS REPORT, JUNE 1958

, 1958
J.C. Bresee, P.A. Haas, C.D. Watson, M.E. Whatley   +3 more
openalex   +2 more sources

CHEMICAL TECHNOLOGY DIVISION, UNIT OPERATIONS SECTION MONTHLY PROGRESS REPORT, FEBRUARY 1962 [PDF]

, 1962
M.E. Whatley, P.A. Haas, R.W. Horton, A.D. Ryon, J.C. Suddath, C.D. Watson   +5 more
openalex   +1 more source

Chemoresistome mapping in individual breast cancer patients unravels diversity in dynamic transcriptional adaptation

Molecular Oncology, EarlyView.
This study used longitudinal transcriptomics and gene‐pattern classification to uncover patient‐specific mechanisms of chemotherapy resistance in breast cancer. Findings reveal preexisting drug‐tolerant states in primary tumors and diverse gene rewiring patterns across patients, converging on a few dysregulated functional modules. Despite receiving the
Maya Dadiani, Gilgi Friedlander, Gili Perry, Nora Balint‐Lahat, Shlomit Gilad, Dana Morzaev‐Sulzbach, Anjana Shenoy, Noa Bossel Ben‐Moshe, Anya Pavlovsky, Rinat Bernstein‐Molho, Eytan Domany, Iris Barshack, Tamar Geiger, Bella Kaufman, Einav Nili Gal‐Yam   +14 more
wiley   +1 more source

Nuclear Standards for Chemistry and Technology- Nuclear Standards for Industry, Science, Government, and Consumer: Proceedings of a Symposium held at the 156th National Meeting of the American Chemical Society, Atlantic City, New Jersey, September 8--9, 1968

, 1968
H. F. Beeghly, James J. Cali, W. Wayne Meinke   +2 more
openalex   +2 more sources

Tonic signaling of the B‐cell antigen‐specific receptor is a common functional hallmark in chronic lymphocytic leukemia cell phosphoproteomes at early disease stages

Molecular Oncology, EarlyView.
B‐cell chronic lymphocytic leukemia (B‐CLL) and monoclonal B‐cell lymphocytosis (MBL) show altered proteomes and phosphoproteomes, analyzed using mass spectrometry, protein microarrays, and western blotting. Identifying 2970 proteins and 316 phosphoproteins, including 55 novel phosphopeptides, we reveal BCR and NF‐kβ/STAT3 signaling in disease ...
Paula Díez, Pablo Juanes‐Velasco, Marina L. García‐Vaquero, Conrad Droste, Alicia Landeira‐Viñuela, Miguel Alcoceba, Helena Fidalgo‐Gómez, Sara Misiego‐Herrero, Almudena Navarro‐Bailón, Mónica Baile, José M. Bastida, Jose Manuel Sanchez‐Santos, Rafael Góngora, Julia Almeida, Marcos Gonzalez‐Diaz, Alberto Orfao, Javier De Las Rivas, Manuel Fuentes   +17 more
wiley   +1 more source